Teva Launches Prednisolone EC TabletsBy Teva Uk Ltd, PRNE
Monday, November 22, 2010
CASTLEFORD, England, November 23, 2010 - We are pleased to announce the launch of a generic version of
Prednisolone enteric-coated (EC) tablets.
Prednisolone EC tablets are a generic version of Deltacortril(R) from
Alliance Pharmaceuticals Limited and are indicated in the treatment of
inflammatory and allergic conditions such as asthma, rheumatoid arthritis and
Prednisolone is available immediately in the award-winning Teva 360
livery, which is designed to aid patient safety, as 2.5mg and 5mg
enteric-coated tablets in pots of 28 tablets.
The Teva retail price for the product is GBP8.57 and GBP8.65 for the
2.5mg and 5mg tablet packs respectively.
Kim Innes, Commercial Director at Teva UK Limited, said, "We are
delighted to be bringing a generic version of this product to the UK market,
and at the same time further broaden our portfolio, which is the widest of
any UK generics supplier."
To find out more about Teva UK Limited, visit www.tevauk.com.
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
It has the widest range of any UK generic pharmaceutical company and markets
solid and liquid dose, injectable and respiratory medicines to healthcare
professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic
drug maker, with a global product portfolio of more than 1,250 molecules and
a direct presence in 59 countries.
Teva's branded businesses focus on neurological, respiratory and women's
health therapeutic areas as well as biologics. Teva's leading innovative
product, Copaxone(R), is the number one prescribed treatment for multiple
sclerosis. Teva employs over 40,000 people around the world and reached $13.9
billion in net sales in 2009.
Notes to Editors: For media enquiries, contact the Teva UK Limited Communications team on
+44(0)1977-628500, or email media.enquiries at tevauk.com.
Tags: Castleford, England, November 23, Teva Uk Ltd, United Kingdom